EHACART
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Advertisement
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
The estimated 24-month nonrelapse mortality was significantly lower in the CAR-T cohort than in the allogeneic HSCT cohort.
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Advertisement
The researchers reported “high rates of durable responses” in most patients who were in high-risk disease subgroups.
Idecabtagene vicleucel led to “deeper and more durable responses” than standard regimens in the KarMMa-3 trial.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
The results showed pembrolizumab was well tolerated, with 23.5% of patients achieving a complete response.
All patients had a complete response after the first infusion, while 67% had a complete response after the second infusion.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
670 Madison Ave.
Manalapan, NJ 07726